# Poolbeg Pharma notify that Schroders PLC increase holding to 5.13%

- Link: https://www.directorstalkinterviews.com/poolbeg-pharma-notify-that-schroders-plc-increase-holding-to-5.13/4121065947
- Published: 2022-05-23T13:54:53+01:00
- Author: Giles

**[Poolbeg Pharma plc](https://www.directorstalkinterviews.com/company/poolbeg-pharma-plc/polb.l)**(
[LON:POLB](https://www.directorstalkinterviews.com/company/poolbeg-pharma-plc/polb.l))
have today announced a TR-1: Notification of major interest in shares. The company
published the note stating [Schroders PLC](https://www.directorstalkinterviews.com/ftse-company/schroders-plc/sdr.l)
now own 25,641,941.00 voting rights, its previous position was under the reportable
threshold. This means that Schroders now hold an indirect interest of 5.128388% 
in Poolbeg Pharma. The transaction took place on the 18th May 2022.

Poolbeg Pharma plc ([LON: POLB](https://www.directorstalkinterviews.com/company/poolbeg-pharma-plc/polb.l),
OTCQB: POLBF), is a clinical stage infectious disease pharmaceutical company with
a unique capital light clinical model which enables them to develop multiple products
faster and more cost effectively than the traditional biotech model.

Poolbeg aspires to become a “one-stop shop” for big pharma to find Phase II ready
products for development and commercialisation.

Share on: